Small molecule · Inhibitor of AAK1 (AP2-associated kinase 1) (AAK1) · developed by Satellos Bioscience
Forazapadin is an orally available, muscle-penetrant small molecule that inhibits AAK1, a kinase. It is being studied in facioscapulohumeral muscular dystrophy (FSHD).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07872306 | Phase 2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Not yet recruiting | MSLE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Facioscapulohumeral Muscular Dystrophy (FSHD)
Updated Oct 25, 2026. Something wrong or missing? Report it on the MSLE page.
See MSLE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MSLE catalysts and pipeline →